ResearcherUniversidade de São PauloActive in the last 2 years
Eduardo M. R. Reis
Matched on ORCID iD 0000-0002-9556-3070; OpenAlex author ID A5000803349. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 9
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper
Papers 6
- LncRNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness and Chemoresistance in Pancreatic Cancer Co-author DOI 10.1101/2025.09.29.679231↗
- Animal models of xenograft-induced cachexia of patient-derived pancreatic cancer: exploring potential new biomarkers and treatment targets Co-author DOI 10.21203/rs.3.rs-4400868/v1↗
- Necroptosis activation is associated with greater methylene blue-photodynamic therapy-induced cytotoxicity in human pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1007/s43630-022-00347-4↗
- Annotation and functional characterization of long noncoding RNAs deregulated in pancreatic adenocarcinoma. Last author DOI 10.1007/s13402-022-00678-5↗
- Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer. Co-author DOI 10.1007/s13402-020-00498-5↗
- Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Last author DOI 10.1186/1476-4598-10-141↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniela S. Daniela Sanchez Bassères · 3 shared papers, 2020–2025 · strength 0.46
- Paper LncRNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness and Chemoresistance in Pancreatic Cancer DOI 10.1101/2025.09.29.679231↗
- Paper Annotation and functional characterization of long noncoding RNAs deregulated in pancreatic adenocarcinoma. DOI 10.1007/s13402-022-00678-5↗
- Paper Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer. DOI 10.1007/s13402-020-00498-5↗
- Thalita Bueno Corrêa · 2 shared papers, 2022–2025 · strength 0.35
- Sandro Mascena Gomes-Filho · 2 shared papers, 2020–2025 · strength 0.34
- Claudiana Lameu · 1 shared paper, 2024 · strength 0.23
- Caio Vinícius Teles Rossini · 1 shared paper, 2024 · strength 0.23
- Daria Raquel Queiroz de Almeida · 1 shared paper, 2023 · strength 0.18
- Letícia Labriola · 1 shared paper, 2023 · strength 0.18
- Vinicius Ferreira da Paixão · 1 shared paper, 2022 · strength 0.12
- Ana Carolina Tahira · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.